PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “GYNECOLOGIC DISEASES”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 73 records · Page 4Linked to original sources
PubMed1987

[Tumor markers in gynecologic diseases].

The tumor markers CA 125, CEA, and CA 153 were measured in the serum of patients with malignant and benign gynecologic diseases. In 90% of 76 serous and endometrioid ovarian carcinomas CA 125 values were elevated (greater than 35 U/ml). In cases with primary tumors the concentrations usually exceeded 500 U/ml. CA 125 levels were also elevated in over 80% of the cases of non-epithelial ovarian malignomas and ovarian metastases. There was also in increase in markers in carcinomas not involving the ovary, as well as in benign ovarian tumors and endometrioses. Observations of the course in cases of ovarian carcinoma showed that this marker was a sensitive indicator of the clinical condition. CA 153 was found to be over the limit of 25 U/ml in 40% of 68 patients with breast cancer. The proportion of elevated values was considerably lower (28%) than in the recurrences (72%). In 72% of the cases CA 153 and CEA were correspondingly elevated or normal, while in 16% only CA 153 was elevated. The results indicate the importance of the markers, above all in aftercare of tumor cases.

Antigens, Neoplasm↗
PubMed1991

[Gynecologic diseases in the rural population of Kazakhstan].

A total of 6153 women living in various rural regions of Kazakhstan were screened for gynecologic diseases. Various diseases were detected in 2366 (38.4%) cases. The highest share of patients was found in the Northern regions, where the villages are particularly far away from medical institutions. 161 patients (2.6%) with genital tuberculosis were detected. This condition was the most incident in the Western regions, where the epidemiologic situation in respect of tuberculosis of humans and agricultural animals is particularly unsatisfactory.

Adult↗
PubMedDate not supplied

Oral superparamagnetic contrast agent (ferumoxsil): tolerance and efficacy in MR imaging of gynecologic diseases.

The purpose of this study was to determine the tolerance and the efficacy of the oral contrast agent ferumoxsil in the assessment of gynecologic diseases. Twenty patients underwent MR imaging at 1.5 T. T1-weighted spin-echo (SE) and T2-weighted fast SE images were obtained before and after ingestion of 600-900 mL of the superparamagnetic negative contrast agent ferumoxsil. No side effects were observed. No statistically significant increase in artifact generation was present in the postcontrast images. The efficacy in bowel marking was significant for the small bowel (P = .0001) and the cecum (P < .01), but not significant in all sequences for the sigmoid. In the postcontrast images, delineation of the uterus, the right-sided adnexa, the lymph nodes, and the pathologic lesions was significantly better (P < .01), but not all sequences showed an improvement in delineation of the other pelvic organs. After administration of ferumoxsil, the level of confidence in diagnosis was significantly higher (P = .0001), but no change in diagnosis was made from the pre- to the postcontrast images. We found the oral contrast agent ferumoxsil to be well tolerated and effective in marking the bowel and in delineating the normal organs as well as the pathologic lesions on pelvic MR images.

Administration, Oral↗
PubMed1995

Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: comparison with CA125.

CA125 II, an improved version of the conventional CA125 was compared with CA125 as to which was more useful in gynecologic disease. In the diagnosis of tumors around the adnexal field (primary epithelial ovarian cancer, metastatic ovarian cancer, benign ovarian tumor and endometrial cyst), CA125 II showed the same sensitivity and specificity as CA125. CA125 II also has high simultaneous reproducibility in the low concentration area. The examination by the receiver operating characteristic curve revealed that CA125 II has higher precision than that of CA125 when it is used for the screening test. In conclusion, CA125 II is a better tumor marker than conventional CA125.

Biomarkers, Tumor↗
PubMed1991

Diagnostic imaging of gynecological diseases: the clinician's view.

The introduction of ultrasonography, computerized tomography, and magnetic resonance imaging has led to tremendous progress in the diagnostic evaluation of gynecologic diseases. Refinements in these techniques have allowed the gynecologist to diagnose unsuspected pathology, define disease and its extent, and select the most appropriate treatment despite limitations in specificity experience and cost. Practically the most appropriate imaging modalities are: ultrasonography for adnexal masses, computerized tomography for advanced cervical cancers, and magnetic resonance imaging for corpus cancers and selected cervical cancers.

Diagnostic Imaging↗
PubMed2000

Changes in thymosin-alpha(1)content in patients with nonspecific gynecologic diseases depending on inflammation type and efficacy of antiinflammatory and immunomodulating therapy.

Plasma content of thymosin-alpha(1)and its circadian variations in patients with inflammatory gynecologic diseases differ from those in healthy donors and depend on the type of inflammation and efficacy of treatment. It is concluded that not only the absolute content of thymic hormones, but also their biorhythmic variations are important for immune regulation.

Adjuvants, Immunologic↗
PubMed1993

[Management of gynecologic diseases within the scope of surgical pelviscopy].

Following the routine use of the diagnostic-operative laparoscopy in the surgical diagnosis and therapy of the lower abdominal pain, the surgeon is confronted with a plethora of gynecological diseases. Due to the unknown appearance, suboptimal therapy follows. Intra-operative consultation of a gynecologist does not necessarily bring the expected solution as there is a lack of gynecological anamnesis and preoperative examination. To avoid insufficient endosurgical diagnosis, therapeutical failures and iatrogenic infertility, the gynecological diagnosis scheme with subsequent therapy is described. Completing the preoperative diagnostics by a gynecological investigation can improve endosurgical treatment and avoid second-look surgery.

Abdominal Pain↗
PubMed1992

Peri- and postoperative changes in serum levels of four tumor markers and three acute phase reactants in benign and malignant gynecological diseases.

Serum levels of squamous cell carcinoma antigen, carcinoembryonic antigen, CA 125, tissue polypeptide antigen, CRP, alpha 1-antitrypsin and haptoglobin were determined peri- and postoperatively in patients undergoing surgery for benign gynecological disease (n = 18) and postoperatively in women operated for cervical carcinoma (n = 23). The only significant changes seen after premedication, during anesthesia and during surgery were a decrease in serum concentrations of alpha 1-antitrypsin and haptoglobin. We found no postoperative changes in the serum levels of squamous cell carcinoma antigen nor in carcinoembryonic antigen values. However, the latter analyte was influenced by smoking habits. Elevated levels of CA 125 and tissue polypeptide antigen were found in the cancer patients, predominantly within the first 1-3 weeks after surgery. These levels decreased to normal values within 4-6 weeks postoperatively. The median intraindividual coefficients of variation for the tumor markers ranged between 15% and 28% in 30 control women not having surgery. In general, it would seem advisable to wait 6 weeks after surgery before monitoring with CA 125 and TPA is started.

Acute-Phase Proteins↗